RNA Interference: Application to Drug Discovery and Challenges to Pharmaceutical Development provides a general overview of this rapidly emerging field, with a strong emphasis on issues and aspects that are important to a drug development team. The first part covers more general background of RNA interference and its application in drug discovery. In the second part, the book addresses siRNA (small interfering RNA), a pharmaceutically potent form, and its use and delivery in therapeutics along with manufacturing and delivery aspects.
PAUL H. JOHNSON, PhD, is a cofounder and Chief Scientific Officer at PhaseRx, Inc. He is the author of numerous scientific papers and patents, and was the recipient of the 2007 Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery.
CONTRIBUTORS. PREFACE. FOREWORD. I. Biology of RNA Interference. 1 RNA Interference: What is it? (James A. Birchler). 2 Nucleic Acids as Regulatory Molecules (Faqing Huang, C. J. Yu, and Yanlin Guo). 3 Use of siRNA Oligonucleotides to Study Gene Function (Kristin A. Wiederholt and Adam N. Harris). 4 Genome Scanning by RNA Interference (Roderick L. Beijersbergen and Oliver C. Steinbach). II Development of siRNA for Therapeutic Applications. 5 Discovery of New siRNA Delivery Agents (Paul H. Johnson, Diane Frank, Kunyuan Cui, Roger Adami, Harry Wang, Michael Houston, and Steven C. Quay). 6 siRNA Delivery Vehicles (Aliasger K. Salem and Mark A. Behlke). 7 Interferon, Cytokine Induction and Other Potential In Vivo Toxicities (Adam Judge, Marjorie Robbins, and Ian MacLachlan). 8 Application of RNA Interference to Viral Diseases (Ralph A. Tripp and Stephen Mark Tompkins). Index.